These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 25378634)

  • 1. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
    Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
    Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
    Lee YE; Choi SA; Kwack PA; Kim HJ; Kim IH; Wang KC; Phi JH; Lee JY; Chong S; Park SH; Park KD; Hwang DW; Joo KM; Kim SK
    Neuro Oncol; 2017 Aug; 19(8):1079-1087. PubMed ID: 28340172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfiram potentiates the anticancer effect of cisplatin in atypical teratoid/rhabdoid tumors (AT/RT).
    Jangra A; Choi SA; Yang J; Koh EJ; Phi JH; Lee JY; Wang KC; Kim SK
    Cancer Lett; 2020 Aug; 486():38-45. PubMed ID: 32428661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
    Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
    Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of disulfiram and H
    Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
    Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
    Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenase.
    Choi SA; Lee JY; Phi JH; Wang KC; Park CK; Park SH; Kim SK
    Eur J Cancer; 2014 Jan; 50(1):137-49. PubMed ID: 24103144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
    Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents.
    Banderali U; Jayanthan A; Hoeksema KA; Narendran A; Giles WR
    J Neurooncol; 2012 Mar; 107(1):111-9. PubMed ID: 21971736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.
    Yao W; Qian X; Ochsenreither S; Soldano F; DeLeo AB; Sudhoff H; Oppel F; Kuppig A; Klinghammer K; Kaufmann AM; Albers AE
    Cells; 2021 Feb; 10(3):. PubMed ID: 33671083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
    Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
    Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thiocarbamate disulphide drug, disulfiram induces osteopenia in rats by inhibition of osteoblast function due to suppression of acetaldehyde dehydrogenase activity.
    Mittal M; Khan K; Pal S; Porwal K; China SP; Barbhuyan TK; Baghel KS; Rawat T; Sanyal S; Bhadauria S; Sharma VL; Chattopadhyay N
    Toxicol Sci; 2014 May; 139(1):257-70. PubMed ID: 24496638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
    Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
    Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
    Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
    Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
    Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
    Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.
    Venneti S; Le P; Martinez D; Xie SX; Sullivan LM; Rorke-Adams LB; Pawel B; Judkins AR
    Am J Surg Pathol; 2011 Oct; 35(10):1463-72. PubMed ID: 21921784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Adipose Tissue-Derived Mesenchymal Stem Cells Target Brain Tumor-Initiating Cells.
    Choi SA; Lee JY; Kwon SE; Wang KC; Phi JH; Choi JW; Jin X; Lim JY; Kim H; Kim SK
    PLoS One; 2015; 10(6):e0129292. PubMed ID: 26076490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC.
    Wu L; Meng F; Dong L; Block CJ; Mitchell AV; Wu J; Jang H; Chen W; Polin L; Yang Q; Dou QP; Wu G
    Sci Rep; 2019 Jan; 9(1):236. PubMed ID: 30659204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.